106 related articles for article (PubMed ID: 2975605)
1. Evidence for homogeneity of thromboxane A2 receptor using structurally different antagonists.
Swayne GT; Maguire J; Dolan J; Raval P; Dane G; Greener M; Owen DA
Eur J Pharmacol; 1988 Aug; 152(3):311-9. PubMed ID: 2975605
[TBL] [Abstract][Full Text] [Related]
2. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.
Narumiya S; Okuma M; Ushikubi F
Br J Pharmacol; 1986 Jun; 88(2):323-31. PubMed ID: 3730697
[TBL] [Abstract][Full Text] [Related]
3. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to guinea-pig platelets.
Halushka PV; Mais DE; Garvin M
Eur J Pharmacol; 1986 Nov; 131(1):49-54. PubMed ID: 3816947
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
5. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
Mais DE; Kochel PJ; Saussy DL; Halushka PV
Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
[TBL] [Abstract][Full Text] [Related]
6. Increased platelet thromboxane A2/prostaglandin H2 receptors in patients with acute myocardial infarction.
Dorn GW; Liel N; Trask JL; Mais DE; Assey ME; Halushka PV
Circulation; 1990 Jan; 81(1):212-8. PubMed ID: 2137044
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist.
Ford-Hutchinson AW; Girard Y; Lord A; Jones TR; Cirino M; Evans JF; Gillard J; Hamel P; Leveillé C; Masson P
Can J Physiol Pharmacol; 1989 Sep; 67(9):989-93. PubMed ID: 2598135
[TBL] [Abstract][Full Text] [Related]
9. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.
Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J
Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557
[No Abstract] [Full Text] [Related]
10. Characterization of a thromboxane A2/prostaglandin H2 receptor in guinea pig lung membranes using a radioiodinated thromboxane mimetic.
Saussy DL; Mais DE; Dubé GP; Magee DE; Brune KA; Kurtz WL; Williams CM
Mol Pharmacol; 1991 Jan; 39(1):72-8. PubMed ID: 1824791
[TBL] [Abstract][Full Text] [Related]
11. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
12. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
[TBL] [Abstract][Full Text] [Related]
14. BAY u3405, a potent and selective thromboxane A2 receptor antagonist on airway smooth muscle in vitro.
McKenniff MG; Norman P; Cuthbert NJ; Gardiner PJ
Br J Pharmacol; 1991 Nov; 104(3):585-90. PubMed ID: 1839139
[TBL] [Abstract][Full Text] [Related]
15. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.
Dorn GW; Burch RM; Kochel PJ; Mais DE; Halushka PV
Biochem Pharmacol; 1987 Jun; 36(12):1913-7. PubMed ID: 2954555
[TBL] [Abstract][Full Text] [Related]
16. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
Mallarkey G; Smith GM
Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.
Ogletree ML; Harris DN; Greenberg R; Haslanger MF; Nakane M
J Pharmacol Exp Ther; 1985 Aug; 234(2):435-41. PubMed ID: 3926986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
